This 123b-33bcCAR was designed to deplete AML cells by targeting both bulky disease and the CD34+CD38−CD123+ leukemic population to eliminate active disease and prevent leukemia relapses (Fig. 1c). The gene discussed is CD34; the disease is acute myeloid leukemia.